Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.

Clicks: 274
ID: 100823
2020
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent. In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19.
Reference Key
xu2020broadacs Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Xu, Jimin;Shi, Pei-Yong;Li, Hongmin;Zhou, Jia;
Journal ACS infectious diseases
Year 2020
DOI
10.1021/acsinfecdis.0c00052
URL
Keywords
human adenovirus mers-cov coronavirus zika virus flavivirus sars-cov ebola virus sars-cov-2 (covid-19) broad antiviral agents niclosamide

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.